The TISIDB database showed that NCAPD2 expression was higher in responders than in nonresponders in urothelial carcinoma treated with the PD-L1 inhibitor atezolizumab (Figure 7A). The gene discussed is NCAPD2; the disease is urothelial carcinoma.